Company intelligence / Profile preview

Visgenx

Santa Cruz, California, United Statesvisgenx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Visgenx is developing gene therapies focused on increasing expression of the ELOVL2 gene to regulate aging in the retina and potentially slow or halt the progression of conditions like Dry Age-Related Macular Degeneration. Their lead candidate VGX-0111 was discontinued, but they have other ELOVL2-based therapies in preclinical development.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAAV-based gene therapy
Industry: Biotech

Drug pipeline

2 assets

AAV8 ELOVL2 gene therapy

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Visgenx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Visgenx.

Explore the full profile